A Randomized, Double-blind, Placebo-controlled, Forced Dose-escalation, Multi-center Pilot Study to Evaluate the Lipid Regulating Effects of TRIA-662 (1-methylnicotinamide Chloride)

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Forced Dose-escalation, Multi-center Pilot Study to Evaluate the Lipid Regulating Effects of TRIA-662 (1-methylnicotinamide Chloride)

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Feb 2016

At a glance

  • Drugs N-1-methylnicotinamide (Primary)
  • Indications Hyperlipidaemia
  • Focus Therapeutic Use
  • Sponsors Cortria Corporation
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 26 Jan 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 03 Aug 2015 Planned End Date changed from 1 Sep 2015 to 1 Oct 2015 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top